#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Michael Kaiser Email
VP, Head Investor Relations and Corporate Communications . Hookipa Pharma
Vienna,
Locationm*************@hookipapharma.com
Primary EmailHow to contact Michael Kaiser
Join and see Michael's contact info for free!Current Roles
Employees:
181Revenue:
$19.7MAbout
Hookipa Pharma Inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. With this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. Our Arenavirus technologies, Vaxwave®, a replication-deficient viral vector, and TheraT®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and CD8+ T cells. Both, Vaxwave® and TheraT®, can be administered repeatedly while maintaining their efficacy. TheraT® induced CD8+ T cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive T cell therapy. Hookipa?s ?off-the shelf? viral vectors are administered systemically. They target dendritic cells in vivo and activate the immune system. In immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). At Hookipa we have successfully completed a Phase 1 trial of a Vaxwave®-based prophylactic vaccine to protect against cytomegalovirus (CMV) infections. A proof-of concept trial in solid organ transplant patients will start imminently. We have forged a landmark partnership with Gilead Sciences Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. We are building a proprietary immune-oncology pipeline by targeting TheraT® towards HPV+ head and neck squamous cell carcinoma and prostate cancer.Hookipa Pharma Address
350 Fifth AvenueVienna, null
Austria